BRPI0820474B8 - uso do composto 1-[2-(2,4-dimetil-fenil-sulfanil)-fenil]-piperazina ou de sais farmaceuticamente aceitáveis do mesmo - Google Patents

uso do composto 1-[2-(2,4-dimetil-fenil-sulfanil)-fenil]-piperazina ou de sais farmaceuticamente aceitáveis do mesmo

Info

Publication number
BRPI0820474B8
BRPI0820474B8 BRPI0820474A BRPI0820474A BRPI0820474B8 BR PI0820474 B8 BRPI0820474 B8 BR PI0820474B8 BR PI0820474 A BRPI0820474 A BR PI0820474A BR PI0820474 A BRPI0820474 A BR PI0820474A BR PI0820474 B8 BRPI0820474 B8 BR PI0820474B8
Authority
BR
Brazil
Prior art keywords
phenyl
sulfanyl
piperazine
dimethyl
pharmaceutically acceptable
Prior art date
Application number
BRPI0820474A
Other languages
English (en)
Inventor
Batra Aneil
Chon Jin
Dragheim Marianne
Moore Nicholas
Original Assignee
H Lundbeck As
Takeda Pharmaceuticals North America Inc
Takeda Pharmaceuticals Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0820474(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As, Takeda Pharmaceuticals North America Inc, Takeda Pharmaceuticals Usa Inc filed Critical H Lundbeck As
Publication of BRPI0820474A2 publication Critical patent/BRPI0820474A2/pt
Publication of BRPI0820474B1 publication Critical patent/BRPI0820474B1/pt
Publication of BRPI0820474B8 publication Critical patent/BRPI0820474B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

método de tratamento de uma doença, uso de composto, e, composto. são fornecidos usos farmacêuticos novos de 1-[2-(2,4-dimetil-fenil-sulfanil)-fenil]-piperazina e sais farmaceuticamente aceitáveis do mesmo.
BRPI0820474A 2007-11-13 2008-11-12 uso do composto 1-[2-(2,4-dimetil-fenil-sulfanil)-fenil]-piperazina ou de sais farmaceuticamente aceitáveis do mesmo BRPI0820474B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200701607 2007-11-13
DKPA200701607 2007-11-13
DKPA200701788 2007-12-14
DKPA200701788 2007-12-14
DKPA200801300 2008-09-17
DKPA200801300 2008-09-17
PCT/DK2008/050271 WO2009062517A1 (en) 2007-11-13 2008-11-12 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Publications (3)

Publication Number Publication Date
BRPI0820474A2 BRPI0820474A2 (pt) 2017-05-23
BRPI0820474B1 BRPI0820474B1 (pt) 2020-08-04
BRPI0820474B8 true BRPI0820474B8 (pt) 2021-05-25

Family

ID=40170671

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820474A BRPI0820474B8 (pt) 2007-11-13 2008-11-12 uso do composto 1-[2-(2,4-dimetil-fenil-sulfanil)-fenil]-piperazina ou de sais farmaceuticamente aceitáveis do mesmo

Country Status (30)

Country Link
US (5) US9278096B2 (pt)
EP (3) EP2431039B1 (pt)
JP (2) JP5603244B2 (pt)
KR (1) KR101536023B1 (pt)
CN (1) CN102014908A (pt)
AR (1) AR069260A1 (pt)
AT (1) ATE537829T1 (pt)
AU (1) AU2008323390B2 (pt)
BR (1) BRPI0820474B8 (pt)
CA (1) CA2705163C (pt)
CL (1) CL2008003363A1 (pt)
CO (1) CO6270322A2 (pt)
CY (2) CY1112646T1 (pt)
DK (2) DK2431039T3 (pt)
EA (1) EA027783B1 (pt)
ES (2) ES2591110T3 (pt)
HR (2) HRP20120144T4 (pt)
HU (1) HUE029588T2 (pt)
IL (1) IL205466A (pt)
LT (1) LT2431039T (pt)
MX (1) MX2010004688A (pt)
NZ (1) NZ585247A (pt)
PL (2) PL2431039T3 (pt)
PT (2) PT2431039T (pt)
RS (2) RS52256B2 (pt)
SG (1) SG10201405001XA (pt)
SI (2) SI2431039T1 (pt)
TW (1) TW200932233A (pt)
WO (1) WO2009062517A1 (pt)
ZA (1) ZA201003350B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
CN102639117A (zh) 2009-08-24 2012-08-15 H.隆德贝克有限公司 1-[2-(2,4-二甲基-苯基硫基)-苯基]哌嗪的新组合物
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
AU2012209466C1 (en) * 2011-01-27 2016-06-23 Neuren Pharmaceuticals Limited Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid
JP6078466B2 (ja) 2011-07-21 2017-02-08 学校法人 名城大学 セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット
CN104853755B (zh) 2012-12-13 2017-08-22 H.隆德贝克有限公司 包含沃替西汀和多奈哌齐的组合物
JP6323979B2 (ja) * 2013-01-17 2018-05-16 学校法人 名城大学 うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
CN105339361A (zh) * 2013-05-31 2016-02-17 斯洛文尼亚莱柯制药股份有限公司 用于合成1-(2-((2，4-二甲基苯基)硫代)苯基)哌嗪的新方法
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
EP3082815B1 (en) * 2013-12-20 2018-10-03 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
CN106103418A (zh) 2014-01-31 2016-11-09 埃吉斯药物私人有限公司 沃替西汀盐的制备方法
EP2930171A1 (en) * 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
EP3799873A1 (en) * 2015-07-17 2021-04-07 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
KR20190025556A (ko) 2016-07-01 2019-03-11 하. 룬드벡 아크티에셀스카브 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법
JP2023520016A (ja) 2020-04-03 2023-05-15 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko) 2022-04-18 2023-10-25 영진약품 주식회사 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US5258387A (en) * 1990-08-21 1993-11-02 Hoffmann-La Roche Inc. Tricyclic pyridone derivatives
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CN100457738C (zh) * 2001-12-20 2009-02-04 H·隆德贝克有限公司 芳氧基苯基和芳硫基苯基衍生物
AU2004226838B8 (en) 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
US20060019938A1 (en) 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
PL2044043T5 (pl) 2006-06-16 2022-05-02 H. Lundbeck A/S Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
CN102639117A (zh) 2009-08-24 2012-08-15 H.隆德贝克有限公司 1-[2-(2,4-二甲基-苯基硫基)-苯基]哌嗪的新组合物

Also Published As

Publication number Publication date
ES2379419T3 (es) 2012-04-25
AR069260A1 (es) 2010-01-06
PT2219647E (pt) 2012-03-16
NZ585247A (en) 2012-03-30
CL2008003363A1 (es) 2009-06-05
DK2219647T4 (da) 2020-09-28
EP2219647B1 (en) 2011-12-21
RS55147B1 (sr) 2016-12-30
US20110201617A1 (en) 2011-08-18
PL2219647T3 (pl) 2012-07-31
EP2431039B1 (en) 2016-07-20
CA2705163A1 (en) 2009-05-22
EA201070598A1 (ru) 2010-10-29
CY1112646T1 (el) 2016-02-10
HRP20120144T4 (hr) 2020-11-13
PL2431039T3 (pl) 2016-12-30
BRPI0820474A2 (pt) 2017-05-23
KR101536023B9 (ko) 2023-03-29
LT2431039T (lt) 2016-10-10
SI2219647T2 (sl) 2020-11-30
HRP20161121T1 (hr) 2017-01-27
US9278096B2 (en) 2016-03-08
CA2705163C (en) 2013-02-12
RS52256B (en) 2012-10-31
JP2011503125A (ja) 2011-01-27
ES2591110T3 (es) 2016-11-24
MX2010004688A (es) 2010-09-09
HUE029588T2 (en) 2017-03-28
TW200932233A (en) 2009-08-01
BRPI0820474B1 (pt) 2020-08-04
KR101536023B1 (ko) 2015-07-10
DK2219647T3 (da) 2012-03-19
HRP20120144T1 (en) 2012-04-30
EP3115050A1 (en) 2017-01-11
IL205466A (en) 2014-06-30
RS52256B2 (sr) 2020-11-30
JP2014193891A (ja) 2014-10-09
PT2431039T (pt) 2016-09-29
SG10201405001XA (en) 2014-10-30
DK2431039T3 (en) 2016-09-26
ZA201003350B (en) 2011-08-31
AU2008323390A1 (en) 2009-05-22
WO2009062517A1 (en) 2009-05-22
US20160228430A1 (en) 2016-08-11
JP5841636B2 (ja) 2016-01-13
CY1117978T1 (el) 2017-05-17
KR20100099115A (ko) 2010-09-10
AU2008323390B2 (en) 2013-10-24
ES2379419T5 (es) 2021-05-04
EP2219647A1 (en) 2010-08-25
SI2431039T1 (sl) 2017-01-31
EP2219647B2 (en) 2020-07-29
IL205466A0 (en) 2010-12-30
EP2431039A1 (en) 2012-03-21
JP5603244B2 (ja) 2014-10-08
US20180161321A1 (en) 2018-06-14
CN102014908A (zh) 2011-04-13
US20210093631A1 (en) 2021-04-01
CO6270322A2 (es) 2011-04-20
US20240082239A1 (en) 2024-03-14
US9744166B2 (en) 2017-08-29
ATE537829T1 (de) 2012-01-15
SI2219647T1 (sl) 2012-06-29
US11628166B2 (en) 2023-04-18
EA027783B1 (ru) 2017-09-29

Similar Documents

Publication Publication Date Title
BRPI0820474B8 (pt) uso do composto 1-[2-(2,4-dimetil-fenil-sulfanil)-fenil]-piperazina ou de sais farmaceuticamente aceitáveis do mesmo
CY1121043T1 (el) Θεραπευτικες ενωσεις
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
UY32649A (es) "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
BR112015001874A2 (pt) sais e formas sólidas de (s) -3- (4 - ((4-morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e composições que compreendem e métodos de utilização das mesmas
WO2006102308A3 (en) Beta-lactamyl vasopressin v1b antagonists
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
BRPI0923728A2 (pt) "método de preparação de compostos de di-hidroindeno amida, suas composições farmacêuticas contendo esses compostos e uso como inibidor de proteína quinase".
BRPI0813897A2 (pt) Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, seqüência de nucleotídeos.
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
BR112012003462A2 (pt) "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
EA201171287A1 (ru) Жидкие составы солей 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
UY29952A1 (es) Composiciones faramacéuticas que comprenden 4-(4-fluoro-2-metil-1h-indol-5-iloxi)-6-metoxi-7-(3-(pirrolidin-1-il)propoxi)quinazolina o una sal farmacéuticamente aceptable del mismo, procesos de preparación y uso
CR20120058A (es) Composiciones nuevas de 1 - [2 - (2,4-dimetil-fenilsulfanil)-fenil] piperazina
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
FR2932486B1 (fr) Procede de preparation d'un polyamideimide, polyamideimide et composition comprenant ce polyamideimide.
CY1112173T1 (el) Η χρηση της cilobradine ή των φαρμακευτικα αποδεκτων αλατων αυτης για την θεραπεια ή την προληψη της καρδιακης ανεπαρκειας
CY1118886T1 (el) Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης
SE0302546D0 (sv) New compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: H. LUNDEBECK A/S (US) ; TAKEDA PHARMACEUTICALS U.S

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: LIBBS FARMACEUTICA LTDA - 870210011554 - 03/02/2021

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.000768/2022-78 ORIGEM: JUIZO SUBSTITUTO DA 13A VF DO RIO DE JANEIRO (TRF2) PROCESSO NO: 5083535-29.2021.4.02.5101 NULIDADE DE PATENTE DE INVENCAO AUTOR: ALTHAIA S.A INDUSTRIA FARMACEUTICA REU(S): H. LUNDBECK A/S, TAKEDA PHARMACEUTICALS U.S.A., INC. E INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.007244/2021-27 ORIGEM: 21A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1049910-61.2021.4.01.3400 ACAO DE PROCEDIMENTO COMUM COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: H. LUNDBECK A/S E TAKEDA PHARMACEUTICALS U.S.A., INC. REU(S): LIBBS FARMACEUTICA LTDA E INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL